Centene Corporation delivered robust revenue growth of nearly 20% in FY2025, primarily fueled by expanded Medicaid membership and Health Insurance Marketplace enrollment. However, this topline success belies significant pressure on profitability, with operating income plunging into a $7.6 billion loss, largely from accelerated medical cost trends and impairment charges tied to the Magellan Health divestiture. The company’s health benefits ratio expanded sharply amid rising acuity, increased pharmaceutical costs, and state policy shifts such as carve-ins and Medicaid redeterminations following the pandemic public health emergency. Despite positive operating cash flows and ongoing capital discipline evidenced by moderated share repurchases, return on equity turned negative, highlighting the tension between scale growth and margin compression. Centene’s integrated local approach and focused Medicare D-SNP strategy offer a foundation for medium-term recovery, though near-term risks remain from regulatory uncertainty and membership changes.